Haemoglobin response to subcutaneous versus intravenous epoetin alfa administration in iron-replete haemodialysis patients

Nephrology

Volumn 9, Issue 3, 2004, Pages 153-160

  Leikis, Murray J ^a,b   Kent, Annette B ^a   Becker, Gavin J ^a,b   McMahon, Lawrence P ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Anaemia; Chronic kidney disease; Erythropoietin; Intravenous; Randomized trial; Subcutaneous

Indexed keywords

FERRITIN; FERRUM H; HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; FLU LIKE SYNDROME; HEART PALPITATION; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; CROSS-OVER STUDIES; EPOETIN ALFA; FEMALE; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 3042753139     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00251.x     Document Type: Article

References (37)

1. Hsu CY, Bates DW, Kuperman GJ, Curhan GC. Relationship between hematocrit and renal function in men and women. Kidney Int. 2001; 59: 725-31.
2. Ma JZ, Ebben J, Xia H, Collins AJ. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 1999; 10: 610-19.
3. Xia H, Ebben J, Ma JZ, Collins AJ. Hematocrit levels and hospitalization risks in hemodialysis patients. J. Am. Soc. Nephrol. 1999; 10: 1309-16.
4. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996; 28: 53-61.
5. Levin A, Singer J, Thompson CR, Ross H, Lewis M. Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am. J. Kidney Dis. 1996; 27: 347-54.
6. McMahon LP, McKenna MJ, Sangkabutra T et al. Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol. Dial. Transplant. 1999; 14: 1182-7.
7. Pickett JL, Theberge DC, Brown WS, Schweitzer SU, Nissenson AR. Normalizing hematocrit in dialysis patients improves brain function. Am. J. Kidney Dis. 1999; 33: 1122-30.
8. Schaefer RM, Kokot F, Wernze H, Geiger H, Heidland A. Improved sexual function in hemodialysis patients on recombinant erythropoietin: A possible role for prolactin. Clin. Nephrol. 1989; 31: 1-5.
9. Besarab A, Flaharty KK, Erslev AJ et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: The case for subcutaneous administration. J. Am. Soc. Nephrol. 1992; 2: 1405-16.
10. Schaller R, Sperschneider H, Thieler H et al. Differences in intravenous and subcutaneous application of recombinant human erythropoietin: A multicenter trial. Artif. Organs 1994; 18: 552-8.
11. Paganini EP, Eschbach JW, Lazarus JM et al. Intravenous versus subcutaneous dosing of epoetin alfa in hemodialysis patients. Am. J. Kidney Dis. 1995; 26: 331-40.
12. Muirhead N, Churchill DN, Goldstein M et al. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease. Am. J. Nephrol. 1992; 12: 303-10.
13. Brockmoller J, Kochling J, Weber W, Looby M, Roots I, Neumayer HH. The pharmacokinetics and pharmacodynamics of recombinant human erythropoietin in haemodialysis patients. Br. J. Clin. Pharmacol. 1992; 34: 499-508.
14. Stockenhuber F, Loibl U, Gottsauner-Wolf M et al. Pharmacokinetics and dose-response after intravenous and subcutaneous administration of recombinant erythropoietin in patients on regular haemodialysis treatment or continuous ambulatory peritoneal dialysis. Nephron 1991; 59: 399-402.
15. Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am. J. Kidney Dis. 2002; 40: 439-46.
16. Jacobs C, Hörl WH, Macdougall IC et al. European Best Practice Guidelines 9-13 Anaemia Management. Nephrol. Dial. Transplant. 2000; 15 (Suppl. 4): 33-42.
17. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant erythropoietin. N. Engl. J. Med. 2002; 346: 469-75.
18. Cody J, Daly C, Campbell M et al. Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients (Cochrane Review). Cochrane Database Syst. Rev. 2002; 4: CD003895.
19. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995; 26: 41-6.
20. Macdougall IC, Tucker B, Thompson J, Tomson CR, Baker LR, Raine AE. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int. 1996; 50: 1694-9.
21. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am. J. Kidney Dis. 1999; 34 (4 Suppl. 2): S40-6.
22. Besarab A, Amin N, Ahsan M et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J. Am. Soc. Nephrol. 2000; 11: 530-8.
23. Chang CH, Chang CC, Chiang SS. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin. Nephrol. 2002; 57: 136-41.
24. CARI Guidelines. CARI Guidelines, 2003. Available from: http://www.kidney.org.au/cari/index.htm.
25. Anonymous. European best practice guidelines for the management of anaemia in patients with chronic renal failure. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure. Nephrol. Dial. Transplant. 1999; 14 (Suppl. 5): 1-50.
26. K/DOQI. CARI Guidelines, 2003 Available from: http://www.kidney.org/ professionals/doqi/
27. Tomson CR, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in haemodialysis patients. Nephrol. Dial Transplant. 1992; 7: 129-32.
28. Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur. J. Clin. Pharmacol. 1996; 50: 171-7.
29. Taylor JE, Belch JJ, Fleming LW, Mactier RA, Henderson IS, Stewart WK. Erythropoietin response and route of administration. Clin. Nephrol. 1994; 41: 297-302.
30. Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N. Engl. J. Med. 1998; 339: 578-83.
31. Besarab A, Kaiser JW, Frinak S. A study of parenteral iron regimens in hemodialysis patients. Am. J. Kidney Dis. 1999; 34: 21-8.
32. Mori H, Hiraoka K, Yorifuji R et al. Adsorption of human recombinant erythropoietin on dialysis membranes in vitro. Artif Organs 1994; 18: 725-8.
33. Cheung AK, Hohnholt M, Leypoldt JK, DeSpain M. Hemodialysis membrane biocompatibility: The case of erythropoietin. Blood Purif. 1991; 9: 153-63.
34. Petersen J, Kang MS, Hays MT. Erythropoietin can be administered during dialysis. A kinetic analysis. ASAIO J. 1996; 42: 27-33.
35. Elston O, Macdougall IC. Body mass is a significant factor in the response to IV or SC EPO. ASN Abstract A1390. J. Am. Soc. Nephrol. 2000; 11: A265.
36. Eschbach JW, Egrie JC, Downing MR, Browne JK, Adamson JW. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial. N. Engl. J. Med. 1987; 316: 73-8.
37. McMahon LP, Mason K, Skinner SL, Burge CM, Grigg LE, Becker GJ. Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure. Nephrol. Dial. Transplant. 2000; 15: 1425-30.